insights_auto
Why is BEAM down 4.99%?
Dive Deeperchevron_right
BEAM:NASDAQ
Beam Therapeutics Inc
$22.83
arrow_downward
-4.99%(-1.20) 1D
Nov 13, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BEAM...
Open
$24.03
High
$24.06
Low
$22.81
Mkt. cap
2.36B
Avg. vol.
1.90M
Volume
2.05M
52-wk high
$38.26
52-wk low
$20.23
EPS
-$1.00
Beta
2.23
Shares outstanding
103.50M
No. of employees
557
Open
$24.03
High
$24.06
Low
$22.81
Mkt. cap
2.36B
Avg. vol.
1.90M
Volume
2.05M
52-wk high
$38.26
52-wk low
$20.23
EPS
-$1.00
Beta
2.23
Shares outstanding
103.50M
No. of employees
557
News stories
From web sources and news partners
Yahoo Finance
·
3 days ago
BEAM Stock Falls 7% Despite Meeting Primary Endpoints in SCD Study
Investing.com
·
3 days ago
H.C. Wainwright reiterates Buy on Beam Therapeutics stock on trial data
Profile
Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks. Wikipedia
About Beam Therapeutics Inc
CEOJohn Evans
Employees557
Founded2017
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitebeamtx.com